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OAConnective tissue growth factor (CTGF; also known as CCN2) is an inﬂammatory mediator, and shows elevated
levels in regions of severe injury and inﬂammatory diseases. CTGF is abundantly expressed in osteoarthritis (OA).
Migration and inﬁltration of mononuclear cells to inﬂammatory sites are playing important roles during OA
pathogenesis. Monocyte chemoattractant protein-1 (MCP-1/CCL2) is the key chemokine that regulates migra-
tion and inﬁltration of monocytes. However, the effect of CTGF on MCP-1 expression and monocyte migration
is largely unknown. Our results showed that MCP-1 was highly expressed in OA synovial ﬁbroblasts (OASFs)
as compared with normal SFs. Directly applying OASFs with CTGF increased MCP-1 expression in a concentra-
tion- and a time-dependent manner. CTGF mediated MCP-1 production was attenuated by αvβ5 integrin
neutralized antibody. Pretreatment with focal adhesion kinase (FAK), MEK, AP-1, and NF-κB inhibitors also
inhibited the potentiating action of CTGF. CTGF-mediated increase of NF-κB and AP-1 luciferase activity was
inhibited by FAK, MEK, and ERK inhibitors or mutants. In vitro chemotaxis assay showed that OA synovial
ﬂuid and supernatants from CTGF treated OASFs increased migration of monocyte. In addition, CTGF-mediated
migrationwas inhibited by the FAK andMEK inhibitors. Taken together, our results indicated that CTGF enhances
the migration of monocyte cells by increasingMCP-1 expression through theαvβ5 integrin, FAK, MEK, ERK, and
NF-κB/AP-1 signal transduction pathway.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Osteoarthritis (OA) is the most common form of arthritis, and is the
single most important cause of disability in older adults [1]. The cause of
the OA is unclear, although obesity, aging, sex, genetic factors, and injury
have been associated with increased risk of OA [2,3]. The development
and progression of OA are now believed to involve inﬂammation even
in the early stages of the disease [4]. Synovial membrane inﬂammation
may also have a role in the pathophysiology of OA. Biochemicalmediators
found in osteoarthritis synovial ﬁbroblasts (OASFs) that affect the cellular
functions of the knee joint include interleukins (ILs), chemokines, growth
factors, andmatrix metalloproteinases (MMPs) [5]. These mediators pro-
duced by osteoarthritis synovial ﬁbroblasts (OASFs) like cytokines and
chemokines promoted inﬂammation, neovascularization, and cartilage
degradation [6]. Migration and inﬁltration of mononuclear cells toology, School of Medicine, China
aiwan. Tel.: +886 4 22052121
.-M. Chuang),
l rights reserved.inﬂammatory sites are regulated by adhesion molecules, such as mono-
cyte chemoattractant protein-1 (MCP-1) also knownas chemokine ligand
2 (CCL2).
MCP-1 belongs to the CC chemokine family. MCP-1 is one of the key
factors involved in the initiation of inﬂammation. It triggers chemotaxis
and transendothelial migration of monocytes to inﬂammatory lesions
[7]. The MCP-1 has been implicated in the pathophysiology of such in-
ﬂammatory conditions like atherosclerosis [8], multiple sclerosis, arthritis
and cancers [7] by attracting in the site of inﬂammation mainly mono-
cytes and lymphocytes. The current study showed that the levels of
MCP-1 are increased in the blood, synovial ﬂuid, and synovial tissue of
patients with rheumatoid arthritis (RA) and OA [9–11]. In an animal ex-
periment, it was also indicated that over-expressed MCP-1 could induce
synovitis [12]. Injection of MCP-1 into rabbit joints resulted in marked
macrophage inﬁltration in the affected joint [10]. MCP-1 is believed to
play an important role as proinﬂammatory agent and accumulation of
monocyte in OA synovial ﬂuid and tissue during OA pathogenesis
[13–15].
Connective tissue growth factor (CTGF; also call CCN2) is a mem-
ber of the CCN family, which is a group of secreted multifunctional
proteins that contain high levels of cysteine [16]. It has been shown
that CTGF is associated with several biological functions such as
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mRNA has been found to be up-regulated adjacent to areas of cartilage
surface damage, and present in chondro-osteophytes [18]. In an animal
model, CTGF overexpression in mouse knee joints induces ﬁbrosis and
cartilage damage [19]. The cartilage damage thatwas found could be ei-
ther a direct effect of CTGF overexpression or a result of factors excreted
by the CTGF-induced ﬁbrotic synovial tissue [19]. Therefore, CTGF is a
likely candidate to contribute to the pathogenesis of OA.
Previous studies showed that CTGF promotes inﬂammatory re-
sponse [20,21]. In vitro studies showed that CTGF induces adhesion of
peripheral blood activated monocytes and macrophages mainly in an
integrin-dependent manner. Although a role for CTGF promoting inﬁl-
tration of T lymphocytes and monocytes has been implied for some
cell types, the signaling pathway for CTGF inMCP-1 production andmi-
gration of monocyte in human synovial ﬁbroblasts has not been exten-
sively studied. In the present study, we explored the intracellular
signaling pathway involved in CTGF-induced MCP-1 production in
human synovial ﬁbroblast cells. CTGF increases monocyte migration
and up-regulates MCP-1 expression in human OASF cells. In addition,
αvβ5 integrin, FAK, MEK, ERK, and NF-κB/AP-1 signaling pathways
were involved.2. Materials and methods
2.1. Materials
Anti-mouse and anti-rabbit IgG-conjugated horseradish peroxidase,
rabbit polyclonal antibodies speciﬁc for β-actin, αv, β5, FAK, MEK, ERK,
p-c-Jun, c-Jun, p-IKK, IKK, p-IκB, IκB, p65 and the small interfering RNAs
(siRNAs) against c-Jun, and a control for experiments using targeted
siRNA transfection (each consists of a scrambled sequence that does
not lead to speciﬁc degradation of any known cellularmRNA)were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit poly-
clonal antibodies speciﬁc for p-FAK, p-MEK, p-ERK, p-p65, and ERK
kinase assay kit were purchased from Cell Signaling and Neuroscience
(Danvers, MA). Mouse monoclonal antibodies speciﬁc for αvβ3, αvβ5,
α5β1, andα6β1 integrinwere purchased fromMillipore Biotechnology
(Billerica, MA). The recombinant human CTGF was purchased from
PeproTech (Rocky Hill, NJ, USA). The mouse monoclonal antibodies
speciﬁc for MCP-1 and MCP-1 ELISA kit were purchased from R&D
Systems (Minneapolis, MN). The ON-TARGETplus siRNA of αv integrin,
β5 integrin, and control were purchased from Dharmacon Research
(Lafayette, CO). The NF-κB and AP-1 luciferase plasmids were pur-
chased from Stratagene (La Jolla, CA). The IKKα (KM) and IKKβ (KM)
mutants were provided by Dr. H. Nakano (Juntendo University, Tokyo,
Japan). The phosphorylation site mutant of FAK (Y397F) was provided
by Dr. J.A. Girault (Institut du Fer à Moulin, Moulin, France). The MEK1
dominant-negative mutant was provided by Dr. W.M. Fu (National Tai-
wan University, Taipei, Taiwan). The ERK2 dominant-negative mutant
was provided by Dr. M. Cobb (South-Western Medical Center, Dallas,
TX, USA). The pSV-β-galactosidase vector and luciferase assay kit were
purchased from Promega (Madison, WI). All other chemicals were pur-
chased from Sigma-Aldrich (St. Louis, MO).2.2. Cell culture
We obtained approval from the local ethics committee, and subjects
gave informedwritten consent. Human synovial ﬁbroblasts were isolat-
ed by collagenase treatment of synovial tissue samples obtained from
patients with OA during knee replacement surgeries and samples of
non-arthritic synovial tissues obtained at arthroscopy after trauma/
joint derangement. OASFs were isolated, cultured, and characterized
as previously described [22,23]. Experiments were performed using
cells from passages 3 to 6.THP-1, a human leukemia cell line of monocyte/macrophage lineage,
was obtained from American Type Culture Collection (Manassas, VA,
USA) and grown in RPMI-1640 medium with 10% fetal bovine serum.2.3. Quantitative real-time PCR
Total RNA was extracted from synovial ﬁbroblasts using a TRIzol kit
(MDBio Inc., Taipei, Taiwan). The reverse transcription reaction was
performed using 2 μg of total RNA that was reverse transcribed into
cDNA using oligo (dT) primer [24,25]. The quantitative real-time PCR
(qPCR) analysis was carried out using Taqman® one-step PCR Master
Mix (Applied Biosystems, Foster City, CA). cDNA templates (2 μl) were
added per 25-μl reaction with sequence-speciﬁc primers and Taqman®
probes. Sequences for all target gene primers and probes were pur-
chased commercially (β-actin was used as internal control) (Applied
Biosystems). The qPCR assays were carried out in triplicate on a
StepOnePlus sequence detection system. The cycling conditions in-
volved 10-min polymerase activation at 95 °C, followed by 40 cycles
at 95 °C for 15 s and at 60 °C for 60 s. The threshold was set above
the non-template control background and within the linear phase of
the target gene ampliﬁcation to calculate the cycle number at which
the transcript was detected (denoted CT).2.4. Western blot analysis
Cellular lysates were prepared as described previously [26,27]. Pro-
teins were resolved on SDS-PAGE and transferred to Immobilon
polyvinyldiﬂuoride (PVDF) membranes. The blots were blocked with
4% BSA for 1 h at room temperature and then probed with rabbit
anti-human antibodies against FAK, MEK, ERK, p65 and c-Jun (1:1000)
for 1 h at room temperature. After 3 washes, the blots were subse-
quently incubated with donkey anti-rabbit peroxidase-conjugated sec-
ondary antibody (1:3000) for 1 h at room temperature. The blots were
visualized by enhanced chemiluminescence with Kodak X-OMAT LS
ﬁlm (Eastman Kodak, Rochester, NY). The activities of ERK were deter-
mined using kit from Cell Signaling Technology according to the
manufacturer's instructions.2.5. Measurements of MCP-1 production
Human synovial ﬁbroblasts were cultured in 24-well culture plates.
After reaching conﬂuence, cells were treated with CTGF, and then incu-
bated in a humidiﬁed incubator at 37 °C for 24 h. For examination of the
downstream signaling pathways involved in CTGF treatment, cells were
pretreated with various inhibitors (These inhibitors did not affect cell
viability in human synovial ﬁbroblasts; Supplemental data Fig. S1) for
30 min before CTGF (10 ng/ml) administration. After incubation, the
medium was removed and stored at−80 °C until assay. MCP-1 in the
medium was assayed using the MCP-1 enzyme immunoassay kits,
according to the procedure described by the manufacturer.2.6. Plasmids and constructs
Plasmid pGL2-Basic (Promega, Madison, Wis.) was used to gener-
ate constructs of the human MCP-1 (hMCP-1) promoter. To obtain
phMCP486 which covered positions −486 to +6 DNA fragments
were ampliﬁed by PCR with chemically synthesized oligonucleotides
that corresponded to nucleotides −486 to −456 of the sense strand
5′-GGGCTAGCAAGCTTGAGAGCTCCTTCCTGG-3′, and −17 to +6 of
the antisense strand 5′-GGAGATCTTTCATGCTGGAGGCGAGAGTGC-3′.
Human genomic DNA derived from a healthy adult was used as the
template. The PCR products were digested with NheI and BglII and
cloned into the NheI-BglII site of pGL2-Basic.
Fig. 1. CTGF increases MCP-1 expression in human synovial ﬁbroblasts through αvβ5 integrin. (A & B) The concentration of MCP-1 measured by ELISA showed a signiﬁcantly higher MCP-1
concentration in humanOA synovial ﬂuid and humanOASFsmedium as comparedwith human normal synovial ﬂuid and human normal SFsmedium. (C &D) OASFswere incubatedwith var-
ious concentrations of CTGF for 24 h orwith CTGF (10 ng/ml) for 0, 6, 12, or 24 h. TheMCP-1mRNA expressionwas examined by qPCR. (E & F&G)MCP-1 protein expressionwas examined by
ELISA assay andWesternblotting assay. (H; upper panel)OASFswere co-transfectedwithαv andβ5 siRNA, and theαv andβ5 integrin expressionwas examinedbyWestern blotting. (H)OASFs
were pretreatedwith antibody against integrinαvβ5 integrin (1–10 μg/ml),αvβ3,α5β1, andα6β1 (5 μg/ml) for 30 min or co-transfectedwithαv and β5 siRNA followed by stimulationwith
CTGF for 24 h. TheMCP-1 expressionwas examined by ELISA. Results are expressed as themean±S.E. *: pb0.05 as comparedwith basal level. #: pb0.05 as comparedwith CTGF-treated group.
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Fig. 2. FAK is involved inCTGF-inducedMCP-1 production. (A) OASFswere incubatedwith CTGF for indicated time intervals, and FAKphosphorylationwas examined byWestern blotting.
(B & C) OASFs were pretreated with FAK inhibitor (10 μM) for 30 min or transfected with FAK mutant for 24 h followed by stimulation with CTGF, and FAK phosphorylation or MCP-1
expression was examined by Western blotting, qPCR, or ELISA. (D) OASFs were pretreated with FAK inhibitor for 30 min then incubated with CTGF (10 ng/ml) for 24 h. The MCP-1
was examined byWestern blotting. (D) *: pb0.05 as compared with basal level. #: pb0.05 as compared with CTGF-treated group.
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Human synovial ﬁbroblasts were co-transfectedwith 0.8 μg luciferase
plasmid and 0.4 μg β-galactosidase expression vector. OASFs were grown
to 80% conﬂuence in 12well plates andwere transfected on the following
day by Lipofectamine 2000 (LF2000; Invitrogen). DNA and LF2000 were
premixed for 20 min and then applied to the cells (the transfection
efﬁciency is more than 80% as conﬁrmed by transfection with GFP-
expressing plasmid; Supplemental data Fig. S2). After 24 h transfection,
the cellswere incubatedwith the indicated agents. After a further 24 h in-
cubation, themediawere removed, and cellswerewashedoncewith cold
PBS. To prepare lysates, 100 μl reporter lysis buffer (Promega, Madison,
WI) was added to each well, and cells were scraped from dishes. The su-
pernatant was collected after centrifugation at 13,000 rpm for 2 min.
Aliquots of cell lysates (20 μl) containing equal amounts of protein
(20–30 μg)were placed intowells of an opaque black 96-wellmicroplate.
An equal volume of luciferase substrate was added to all samples, and lu-
minescence was measured in a microplate luminometer. The value of lu-
ciferase activity was normalized to transfection efﬁciency monitored by
the co-transfected β-galactosidase expression vector.
2.8. Synthesis of NF-κB and AP-1 decoy oligonucleotide
We used a phosphorothioate double-stranded decoy oligonucleo-
tide (ODN) carrying the NF-κB-consensus sequence 5′-CCTTGAAGG
GATTTCCCTCC-3′/3′-GGAACTT CCCTAAAGGGAGG-5′. The AP-1 decoy
ODN sequence was 5′-TGTCTGACTCATGTC-3′/3′-ACAGACTGAGTACAG-5′. The AP-1 decoy ODN sequence was 5′-TGTCTGACTCATGTC-3′/
3′-ACAGACTGAGTACAG-5′. The mutated (scrambled) form 5′-TTGC
CGTACCTGACTTAGCC-3′/3′-AACGGCATGGACTGAATCGG-5′ was used
as a control. ODN (5 μM) was mixed with LF2000 (10 μg/ml) for
30 min at room temperature, and the mixture was added to cells in
serum-free medium. After 24 h of transient transfection, the cells
were used for the following experiments.
2.9. Chromatin immunoprecipitation assay
Chromatin immunoprecipitation analysis was performed as de-
scribed previously [28]. DNA immunoprecipitated with an anti-p65 or
c-Jun Ab was puriﬁed and extractedwith phenol–chloroform. The puri-
ﬁed DNA pellet was subjected to PCR. PCR products were then resolved
by 1.5% agarose gel electrophoresis and visualized with UV light. The
primers 5′-CCCATTTGCTCATTTGGTCTCAGC-3′ and 5′-GCTGCTGTCTC
TGCCTCTTATTGA-3′ were utilized to amplify across the human MCP-1
promoter region contain NF-κB and AP-1 binding site (−217 to−8).
2.10. Immunoﬂuorescence staining
Cells were cultured in 12-mmcoverslips. After treatmentwith CTGF,
cells were ﬁxed with 4% paraformaldehyde at room temperature. Fif-
teen minutes later, PBS containing 0.5% Triton X-100 was added to the
cells for 15 min. The cells were then incubated for 1 h with rabbit
anti-c-Jun or anti-p65 (1:100) followed by 1 hwith ﬂuorescein isothio-
cyanate (FITC)-conjugated goat anti-rabbit secondary antibody (1:100;
Fig. 3.MEK and ERK but not p38 and JNK are involved in CTGF-mediated MCP-1 production in synovial ﬁbroblasts. (A; upper panel) OASFs were incubated with U0126 and PD98059 or
transfected with MEK1 and ERK mutant, and ERK phosphorylation was examined by Western blotting. (A) OASFs were pretreated with U0126 (10 μM), PD98059 (10 μM), SB203580
(10 μM), and SP600125 (10 μM) for 30 min or transfected with MEK1 and ERK mutant for 24 h followed by stimulation with CTGF for 24 h. The MCP-1 expression was examined by
qPCR. (B) OASFs were pretreated with U0126 and PD98059 for 30 min or transfected with MEK1 and ERK mutant for 24 h followed by stimulation with CTGF for 24 h. The MCP-1
expressionwas examined by ELISA. (C) OASFswere pretreatedwith U0126 and PD98059 for 30 min then incubatedwith CTGF (10 ng/ml) for 24 h, andMCP-1 expressionwas examined
byWestern blotting. (D) OASFs were incubated with CTGF for indicated time intervals, MEK and ERK phosphorylation was examined byWestern blotting. (E & F) OASFs were incubated
with CTGF for indicated time intervals or pretreated for 30 minwith FAK inhibitor, U0126, and PD98059 followed by stimulationwith CTGF for 60 min. ERK activitywas determinedby the
ERK kinase assay kit. *: pb0.05 as compared with basal level. #: pb0.05 as compared with CTGF-treated group.
1118 S.-C. Liu et al. / Biochimica et Biophysica Acta 1833 (2013) 1114–1124Leinco Technology Inc., St Louis, MO, USA). The FITCwas detected using
a Zeiss ﬂuorescence microscope.
2.11. In vitro chemotaxis assay
Synovial ﬂuids or conditionedmedia obtained from CTGF-treatment
cells or pretreatedwith FAK inhibitor, U0126, and PD98059were placed
in the lower compartment of Transwell cluster plates (Costa Corning,
Cambridge, MA, USA) with two-compartment chambers separated bya polycarbonate membrane ﬁlter. THP-1 cells (5X104 cells) were
added to the upper chamber and incubated at 37 °C for 4 h, then ﬁxed
in 3.7% formaldehyde for 5 min and stained with 0.05% crystal violet
in phosphate-buffered saline (PBS) for 15 min. Cells on the upper side
of the ﬁlters were removed with cotton-tipped swabs and the ﬁlters
were washed with PBS. Cells on the underside of the ﬁlters were exam-
ined and counted under amicroscope. A goat anti-mouseMCP-1 or goat
IgGwas used in the chemotaxis assaymedia to determine the biological
speciﬁcity of the above chemokines produced by the cells to stimulate
Fig. 4. AP-1 and NF-κB are involved in the potentiation of MCP-1 production by CTGF. (A) OASFs were transfected with NF-κB or AP-1 ODN for 24 h and then incubated with CTGF
(10 ng/ml) for 24 h, and MCP-1 expression was examined by qPCR. (B & C) OASFs were pretreated for 30 min with PDTC (10 μM) and TPCK (10 μM) or transfected for 24 h with
IKKα and IKKβ mutant and c-Jun siRNA followed by stimulation with CTGF for 24 h. The MCP-1 expression was examined by qPCR and ELISA. (D) OASFs were pretreated with PDTC
and TPCK for 30 min or transfected for 24 h with c-Jun siRNA then incubated with CTGF (10 ng/ml) for 24 h, and MCP-1 expression was examined by Western blotting. (E) OASFs
were incubated with CTGF for indicated time intervals, and IKKα/β, IκBα, p65, and c-Jun phosphorylation was examined by Western blotting. (F) OASFs were pretreated with FAK
inhibitor, U0126, and PD98059 for 30 min then incubated with CTGF for 1 h. The p65 and c-Jun phosphorylation was examined by Western blotting. *: pb0.05 as compared with
basal level. #: pb0.05 as compared with CTGF-treated group.
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repeated at least three times.
2.12. Statistical analysis
Data were expressed as means±S.E. Statistical analysis was per-
formed with Graphpad Prism 4. Analysis of variance (ANOVA) and un-
paired two-tailed student t test were used to determine the signiﬁcant
differences between the means. pb0.05 was considered signiﬁcant.
3. Results
3.1. CTGF induces MCP-1 expression through αvβ5 integrin in human
synovial ﬁbroblasts
MCP-1 is the key chemokine that regulates migration and inﬁltration
of monocytes. First, we examined human synovial ﬁbroblast tissues for
the expression of the MCP-1 by using ELISA. Concentrations of MCP-1 in
synovial ﬂuid were signiﬁcantly higher in patients with OA than in con-
trols (Fig. 1A). The medium from OASFs showed signiﬁcant expression
of MCP-1, which was higher than that in medium from normal SFs
(Fig. 1B). CTGF has been shown to play important role inOA pathogenesis
[29,30]. Next, we directly apply CTGF in OASFs and examine the ex-
pression of MCP-1. Treatment of OASFs with CTGF (1–30 ng/ml) for
24 h induced MCP-1 mRNA and protein expression in a concentration-
dependentmanner (Fig. 1C, E, G) and time-dependent (Fig. 1D, F, G)man-
ner. Previous studies showed that CTGF affects cell functions through
integrin receptor signaling [31,32]. We therefore hypothesized that
integrin receptor signaling pathway may be involved in CTGF-mediated
MCP-1 expression in OASFs. Pretreatment of cells for 30 min with
anti-αvβ5 monoclonal antibody (mAb) markedly reversed the CTGF-
induced MCP-1 production but not through αvβ3, α5β1, and α6β1
integrins (Fig. 1H). In this study, we can't rule out the off-target ef-
fect of αvβ5 antibody. However, the data from speciﬁc αv and β5
siRNA was provided [ON-TARGETplus αv and β5 siRNA (The design of
ON-TARGETplus siRNA can prevent off-target effects of siRNA)]. Co-
transfectionαv andβ5 siRNA reducedαv andβ5 integrin expression, re-
spectively (Fig. 1H). In addition, cotransfectionαv and β5 siRNA reduced
CTGF-mediated MCP-1 expression (Fig. 1H). These results indicate that
CTGF increased MCP-1 expression in human OASFs via αvβ5 integrin
receptor.
3.2. Involvement of FAK in CTGF-induced MCP-1 expression
FAK is a tyrosine kinase considered to be a central molecule in
integrin-mediated signaling [33]. First, we directly measured the phos-
phorylation of FAK in response to CTGF. Treatment of OASFs with CTGF
induced the phosphorylation of FAK (Tyr397) in a time-dependentman-
ner (Fig. 2A). To further determine whether FAK is involved in CTGF-
triggered MCP-1 production, the FAK inhibitor and FAK mutant were
used. Pretreatment of cells for 30 minwith FAK inhibitor or transfection
of cells for 24 hwith FAKmutant reduced CTGF-inducedMCP-1 expres-
sion and FAK phosphorylation (Fig. 2B & C). In addition, FAK inhibitor
also reduced CTGF-induced MCP-1 expression by immunoblot analysis
(Fig. 2D). Based on these results, CTGF appears to act through a αvβ5
integrin receptor and FAK-dependent signaling pathway to enhance
MCP-1 expression in human synovial ﬁbroblasts.Fig. 5. FAK, MEK, and ERK pathways are involved in CTGF-induced AP-1 and NF-κB activation. (
pretreated with FAK inhibitor, U0126, and PD98059 or cotransfeced with FAK, MEK1, and ERK m
were pretreated with FAK inhibitor, U0126, and PD98059 then stimulated with CTGF for 120
immunoprecipitated with anti-c-Jun or p65. One percentage of the precipitated chromatin wa
U0126, and PD98059 then stimulatedwith CTGF for 120 min, and p65 or c-Jun phosphorylation ex
with FAK inhibitor, U0126, and PD98059 for 30 min followed by stimulation with CTGF for 120
transfectedwith humanMCP-1(−486/+6)-luciferase expression vector and then pretreatedwith
incubation with CTGF for 24 h. Luciferase activity was then assayed. *: pb0.05 as compared with3.3. The MEK and ERK signaling pathways are involved in the potentiating
action of CTGF
FAK-dependent mitogen-activated protein kinases (MAPKs) includ-
ing ERK, p38, and JNK activation is involved in the regulation of gene
expression [34–36].We thus investigated the role ofMAPKs inmediating
CTGF-induced MCP-1 expression using the speciﬁc MEK1/2 inhibitors
U0126 and PD98059, p38 inhibitor SB203580, and JNK inhibitor
SP600125. As shown in Fig. 3A, CTGF-induced MCP-1 expression was
markedly attenuated by pretreatment of cells for 30 min with U0126
and PD98059 but not SB203580 and SP600125. The result shows that
CTGF enhancedMCP-1 expression dependent onMEK/ERK speciﬁc path-
way. Pretreatment of cells for 30 min with U0126 and PD98059 also an-
tagonized the potentiating effect of CTGF induced MCP-1 production by
ELISA and immunoblot analysis (Fig. 3B & C). Transfection of cells for
24 h with MEK1 and ERK mutant markedly inhibited the CTGF-induced
MCP-1 production (Fig. 3A & B). In addition, transfection of cells with
MEK1 and ERK mutant or pretreatment of cells with U0126 and
PD98058 reduced basal ERK phosphorylation (Fig. 3A; upper panel).
This data provided evidence that MEK1 and ERK mutant or U0126 and
PD98058 speciﬁc blocked ERK activation. To directly conﬁrm the crucial
role ofMEKand ERK inMCP-1production,wemeasured the level ofMEK
and ERK phosphorylation in response to CTGF. Indeed, treatment of ﬁ-
broblasts with CTGF resulted in a time-dependent phosphorylation of
MEK and ERK (Fig. 3D). The effects of CTGF on ERK activity were directly
assessed by the phosphorylation of one of its substrates ELK-1. In addi-
tion, ERK activity was increased in a time-dependent manner by CTGF
treatment of OASFs (Fig. 3E). Pretreatment of OASFs for 30 min with
FAK inhibitor, U0126, and PD98059 inhibited the CTGF-mediated in-
crease of ERK activity (Fig. 3F). Based on these results, CTGF appears to
act via FAK, MEK, and ERK-dependent signaling pathway to enhance
MCP-1 production in human synovial ﬁbroblasts.
3.4. Involvement of NF-κB and AP-1 in CTGF-induced MCP-1 production
The promoter region of human MCP-1 contains two known cis-
regulatory elements including AP-1 and NF-κB binding sites [37]. CTGF
has been reported to induce gene expression through AP-1 and NF-κB
transactivation [38]. Therefore, we assumed that NF-κB and AP-1 tran-
scriptional activations are involved in CTGF-mediatedMCP-1 expression.
As shown in Fig. 4A, the increase of MCP-1 production by CTGF was an-
tagonized by the cis-element decoy agonist NF-κB binding site (decoy
NF-κB ODN) and AP-1-binding site (decoy AP-1 ODN) but not by scram-
bled decoy (ODN). Therefore, the NF-κB and AP-1 binding sites play im-
portant roles in CTGF-induced MCP-1 production. The role of NF-κB and
AP-1 was further established using the NF-κB inhibitor (PDTC) and IκB
protease inhibitor (TPCK) or IKKα and IKKβmutant or c-Jun siRNA and
showed that these inhibitors, mutants, and siRNA blocked the enhance-
ment of MCP-1 expression induced by CTGF (Fig. 4B–D). In addition,
stimulation of OASFs with CTGF increased IKKα/β, IκBα, p65, and
c-Jun phosphorylation time-dependently (Fig. 4E). Pretreatment of
cells with FAK inhibitor, U0126, and PD98059 markedly inhibited
the CTGF-induced p65 and c-Jun phosphorylation (Fig. 4F).
NF-κB and AP-1 activation was further evaluated by analyzing the
NF-κB and AP-1 luciferase activity, as well as by the chromatin immuno-
precipitation assay. To directly determine whether NF-κB and AP-1 was
activated after CTGF treatment, cells were transiently transfected withA & B) OASFs were transfected with NF-κB and AP-1-luciferase expression vector and then
utant before incubation with CTGF for 24 h. Luciferase activity was then assayed. (C) OASFs
min, and the chromatin immunoprecipitation assay was then performed. Chromatin was
s assayed to verify equal loading (input). (D) OASFs were pretreated with FAK inhibitor,
pression in the nucleuswas determined bywestern blot analysis. (E) OASFs were pretreated
min, and p65 or c-Jun immunoﬂuorescence staining was examined. (F & G) OASFs were
FAK inhibitor, U0126, and PD98059 or cotransfecedwith FAK,MEK1, and ERKmutant before
basal level. #: pb0.05 as compared with CTGF-treated group.
1122 S.-C. Liu et al. / Biochimica et Biophysica Acta 1833 (2013) 1114–1124NF-κB and AP-1 luciferase in OASFs. As shown in Fig. 5A & B, CTGF treat-
ment of cells for 24 h resulted in increased NF-κB and AP-1-luciferase
activity. The increase of NF-κB and AP-1 activity by CTGF was reduced
by FAK inhibitor, U0126, and PD98059 (Fig. 5A & B). Co-transfection of
cells with FAK, MEK1, and ERK mutant also attenuated CTGF-increased
NF-κB and AP-1 luciferase activity (Fig. 5A & B). We next investigated
whether p65 and c-Jun binds to the NF-κB and AP-1 element on the
MCP-1 promoter after CTGF stimulation. The in vivo recruitment of p65
and c-Jun to theMCP-1 promoter was assessed by the chromatin immu-
noprecipitation assay. In vivo binding of p65 to the NF-κB and c-Jun to
the AP-1 element of the MCP-1 promoter occurred after CTGF stimula-
tion (Fig. 5C). The binding of p65 and c-Jun to the NF-κB and AP-1 ele-
ments by CTGF was reduced by FAK inhibitor, U0126, and PD98059
(Fig. 5C). Furthermore to conﬁrm the CTGF activated p65 and c-Jun accu-
mulation in the nucleus,we examined the nuclear versus cytosolic distri-
bution of p65 and c-Jun proteins. Immunoblot analysis showed that FAK
inhibitor, U0126, and PD98059 antagonized the CTGF-induced p-p65
and p-c-Jun accumulate into nucleus (Fig. 5D). Similar results were ob-
served in the images of immunoﬂuorescence staining (Fig. 5E). To
study further the pathways involved in the action of CTGF-induced
MCP-1 expression, transient transfection was performed by using the
human MCP-1(−486/+6) promoter-luciferase construct. Treatment of
cellswith CTGF increases inMCP-1promoter activity (Fig. 5F). FAK inhib-
itor, U0126, and PD98059, FAK, MEK1, and ERK mutants all antagonized
the stimulation of MCP-1 promoter activity by CTGF (Fig. 5F & G).
3.5. Chemotactic effects of the synovial ﬂuid and conditioned media on
monocyte migration
Next, we examine whether CTGF-induced MCP-1 expression pro-
motesmonocytemigration. In vitro chemotaxis assay showedmonocyte
migration in response to the OA synovial ﬂuid (Fig. 6A) and conditioned
media of cells treated with various concentrations of CTGF (Fig. 6B).
When the OA synovial ﬂuid or conditioned media were pre-incubated
with an anti-MCP-1 neutralizing antibodies for 30 min,monocytemigra-
tion was partially attenuated (Fig. 6A & B). These data imply that CTGF
induced MCP-1 expression and promoted monocyte migration. Pre-
treated with FAK inhibitor, U0126, and PD98059 for 30 min decreased
the CTGF-induced chemotactic effects of the conditioned media on
monocyte migration (Fig. 6B). To exclude the net effect of CTGF to regu-
late monocyte migration (because the conditioned media still contains
CTGF recombinant protein), the OASFs were treated with CTGF for 4 h
and then changed with serum free medium for the next 24 h. The
CTGF withdrew-media induced MCP-1 expression (Fig. 6C). In addition,
the inducing expression of MCP-1 promoted monocyte migration and
this effect is attenuated by pretreatment with anti-MCP-1 neutralizing
antibody (Fig. 6D). Taken together, these data suggest that CTGF en-
hances the migration of monocyte cells by increasing MCP-1 expression
in OASF via the αvβ5 integrin, FAK, MEK, ERK, and NF-κB/AP-1 signal
transduction pathway.
4. Discussion
OA is a heterogeneous group of conditions associated with defective
integrity of articular cartilage, in addition to related changes in the under-
lying bone. The chronic inﬂammatory process ismediated through a com-
plex cytokine and chemokine. It is not yet completely understood that all
the factors are responsible for initiating the degradation and loss of the ar-
ticular tissues. CTGFhas been involved in pathologyof arthritis [19]. InOA,
MCP-1 is believed to play an important role as proinﬂammatory agent
and accumulation of leucocytes and monocytes in OA synovial and ﬂuid
to make the synovial inﬂammatory more seriously [13–15]. We con-
ﬁrmed that synovial ﬂuid concentrations of MCP-1 were signiﬁcantly
higher in patientswithOA than in normal ﬂuid samples.We further iden-
tiﬁed MCP-1 as a target protein for the CTGF signaling pathway that reg-
ulates monocyte migration. We showed that potentiation of MCP-1 byCTGF requires activation of the αvβ5 integrin, FAK, MEK, ERK, and
NF-κB /AP-1 signaling pathways. These ﬁndings suggest that CTGF acts
as an inducer of chemokine such as MCP-1 and accumulation of inﬂam-
matory cells to enhance the synovial inﬂammatory response in OA.
Integrins mediate a variety of biologic processes, such as cell adhe-
sion, migration, and invasion [39]. Integrins activated signaling path-
ways and eventually lead to regulation of gene expression, such as
immediate early genes and inﬂammatory cytokines and chemokines
[40,41]. Integrins are known to serve as receptors for CTGF [42]. Pre-
treatment of cells with anti-αvβ5 but not anti-αvβ3, α5β1, and α6β1
mAb inhibited the CTGF-induced MCP-1 production. This indicates that
integrin αvβ5 receptor played an important role in CTGF-induced
MCP-1 expression in OASFs.
Many evidences indicated that integrin binding to ECM proteins or
integrin cross-linking increases tyrosine phosphorylation of FAK
[43,44]. Previous study showed that FAK plays a crucial role in regu-
lating the expression of MCP-1 to upregulate monocyte migration
and inﬂammation [36]. In this study, we demonstrated that CTGF in-
creased phosphorylation of tyrosine 397 of FAK. Furthermore, the FAK
inhibitor antagonized the CTGF-mediated potentiation of MCP-1 ex-
pression. In addition, transfection of OASFs with FAK (Y397F) mutant
reduced CTGF-mediated MCP-1 expression from synovial ﬁbroblasts.
Our data suggest that CTGF induced MCP-1 expression in human
synovial ﬁbroblasts through FAK activation.
To fully elucidate the intracellular signaling events connecting FAK
with MCP-1 secretion including ERK, p38, and JNK [34–36], we showed
in present study that CTGF increased theMEK and ERKphosphorylation.
Pretreatment of cells withMEK inhibitors but not p38 and JNK inhibitor
antagonized the CTGF-inducedMCP-1 expression. Thiswas further con-
ﬁrmed by the result thatMEK1 and ERKmutants inhibited the enhance-
ment ofMCP-1 by CTGF. On the other hand, pretreatment of OASFswith
FAK inhibitor, U0126, and PD98059 inhibited the CTGF-mediated in-
crease of ERK activity. Taken together, our results provide evidence
that CTGF up-regulates MCP-1 in human synovial ﬁbroblasts via the
αvβ5 integrin, FAK, MEK, and ERK signaling pathway.
Previous studies have demonstrated that NF-κB and AP-1 were two
important transcription factors that play a crucial role in immune and in-
ﬂammatory responses [45–48]. The results of this study showed that
NF-κB and AP-1 activation contributes to CTGF-induced MCP-1 produc-
tion in synovial ﬁbroblasts. Pretreatment of cells with NF-κB inhibitors
(PDTC and TPCK) or c-Jun siRNA reduced CTGF-increasedMCP-1 produc-
tion. Therefore, the NF-κB and AP-1 binding sites are important in
CTGF-induced MCP-1 production. Furthermore, CTGF increased the
binding of p65 to the NF-κB element and c-Jun to the AP-1 element on
the MCP-1 promoter, as shown by chromatin immunoprecipitation
assay. Using transient transfection with NF-κB and AP-1-luciferase as
an indicator of NF-κB and AP-1 activity, we also found that CTGF induced
an increase in AP-1 and NF-κB activity. In addition, FAK inhibitor, U0126,
PD98059, FAK, MEK1, and ERK mutants reduced CTGF-increased NF-κB
andAP-1 promoter activity. The same result showed that these inhibitors
andmutants attenuated CTGF-increasedMCP-1 promoter activity. These
results indicate that CTGF might act through the FAK, MEK, ERK, and
NF-κB/AP-1 pathway to induce MCP-1 activation in human OASFs.
Recent studies demonstrate that many OA patients show a changed
morphology and inﬂammatory phenotype in the synovial tissue charac-
terized histologically by hypertrophy and the inﬁltration of leucocytes
and monocytes/macrophages [49,50]. This accumulation of inﬂammato-
ry cells by MCP-1 has been reported to enhance the synovial inﬂamma-
tion and secreted inﬂammatory factors (IL-1, IL-6, IL-8, TNF-α, and PGE2)
and a variety of matrix metalloproteinases, and is thought to play a cen-
tral role in the inﬂammation and joint destruction characteristic of OA. In
this study, we have demonstrated for the ﬁrst time that CTGF mediates
themonocytemigration in OASFs by up-regulation ofMCP-1 production.
These results also indicate that CTGF might act through the αvβ5
integrin, FAK, MEK, ERK, and NF-κB /AP-1 pathway to induce MCP-1 ac-
tivation in human OASFs.
Fig. 6. Conditioned media from the synovial ﬁbroblasts-treated with CTGF promote monocyte migration. (A) Human normal or OA synovial ﬂuid (1:20 dilute) or OA synovial ﬂuid were
pretreatedwith the goat anti-MCP-1 or goat IgG for 30 min, the ability of monocytes (THP-1)migration was assessed by in vitro chemotaxis assay. (B) Conditionedmedia were obtained
by incubating the cells various concentrations of CTGF for 24 h or pretreated with FAK inhibitor, U0126, and PD98059 for 30 min followed by stimulation with CTGF for 24 h. Ability of
monocytes (THP-1) migration was assessed by in vitro chemotaxis assay. Similar studies were performed after the conditioned media were pretreated with the goat anti-MCP-1 or goat
IgG for 30 min. (C) OASFs were incubated with vehicle or CTGF for 4 h and then changed with serum free medium for 24 h. The media were collected and the MCP-1 expression was
examined by ELISA. (D) OASFs were incubated with vehicle or CTGF for 4 h and then changed with serum free medium for 24 h. The media were collected and then incubated with
IgG or MCP-1 neutralizing antibody. Ability of monocytes (THP-1) migration was assessed by in vitro chemotaxis assay. *: pb0.05 as compared with basal level. #: pb0.05 as compared
with CTGF-treated group.
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